

Provider Notice

To: PerformCare MH Clinics, Psychiatrists and CRNPs
From: PerformCare
Date: September 5, 2023
Subject: MH 23 107 Spravato Billing Guidelines

Effective with the issuance of this notice, PerformCare will provide payment for the post dosage observation required to administer intranasal Esketamine, brand name Spravato. Esketamine, (brand name Spravato) is both FDA and DHS approved to treat persons with treatment resistant depression.

Spravato is on PA Medicaid PH -MCO drug formularies, but it requires prior approval from the PH MCO, and when the prescription is filled, the pharmacy bills the Member's PH MCO

Spravato treatment consists of:

- 1) An assessment by a psychiatrist or advanced practitioner, same day, but prior to the Spravato dose administration, billed to PerformCare with the appropriate E & M code.
- 2) The member then self-administers Spravato via nasal inhaler in the presence of the psychiatrist or advanced practitioner.
- 3) The members must then be observed for a minimum of two hours by a health care professional billed to PerformCare per the description and approved rate.

We have also configured our system to add **Medicare Bundled codes** and **rates** to our system as so that we can coordinate benefits for Spravato treatment for dual eligible members. While Medicare has adopted a bundled code and rate that includes the pre dose assessment, the cost of the Spravato medication and the post dosing observation, other primary insurers have plan specific requirements for the various treatment components and billing for the post Spravato dosing observation. There is no standard national code for the minimum of 2 hours of post administration observation of intranasal Esketamine.

Please contact your Account Executive if you have any questions about this Provider Notice.

cc: Lisa Hanzel, Executive Director, PerformCare
Scott Suhring, Capital Area Behavioral Health Collaborative
Missy Reisinger, Tuscarora Managed Care Alliance
PerformCare Account Executives